New Triple-Drug combo aims to control advanced breast cancer
Disease control
Recruiting now
This study tests a new drug called VS-6766 combined with two standard drugs (abemaciclib and fulvestrant) in people with advanced HR+/HER2- breast cancer that has spread. The goal is to find the safest dose and see if the combination helps control the cancer. About 63 participant…
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated May 11, 2026 20:41 UTC